Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?

Intuitive Surgical is in a ~40% drawdown from recent highs, after sales momentum shifted in a more competitive surgical robotics landscape. In Q2 2026 it placed 468 da Vinci robots vs 395 in Q2 2025 (+18%), while da Vinci surgeries performed rose 16% YoY even as the installed base grew 12%, highlighting slower growth in new system adoption. The article argues most revenue is still driven by parts and services (about 75% of Q2 2026 sales vs ~24% new robot sales), partially cushioning the slowdown, and points to AI-assisted surgery as a longer-term upside.

Analysis

The market is likely over-focusing on system placements and underweighting the real moat: utilization of the installed base. If procedure growth keeps outrunning unit growth, that implies higher revenue per robot, better instrument pull-through, and less sensitivity to annual placement volatility than the headline multiple suggests. The competitive threat is real, but it is more likely to show up as slower new-account conversion and lower replacement urgency than as a rapid installed-base migration.

Second-order, the challengers (notably MDT and JNJ) can win share in greenfield hospital decisions without meaningfully impairing existing da Vinci economics. That means the near-term loser is not necessarily ISRG’s annuity stream, but the future growth runway embedded in the terminal multiple: investors may need to de-rate the stock if procedure growth normalizes from teens to high-single digits while placements remain choppy. The bear case is less about share loss today and more about the market paying a premium for a slower compounding profile.

Timing matters. Over days to weeks, the stock can keep underperforming if management commentary frames competition as a longer-duration issue and if placements disappoint again. Over 1-3 quarters, the key falsifier is sustained procedure growth and continued instrument/service outperformance versus system sales; if that holds, this is likely just a multiple reset rather than a structural break. Over 6-18 months, the real debate is whether AI-enabled workflow and surgeon training deepen switching costs enough to re-accelerate utilization and protect margins.

Contrarian view: the consensus may be assuming the robotics market is now a winner-take-most category, when in practice hospitals can add platforms incrementally without ripping out incumbents. That caps upside for entrants, but it also means ISRG’s base case may be sturdier than the current drawdown implies. The stock looks more like a quality compounder facing a slower growth rate than a broken franchise.

Key Decisions for Investors

• Stay cautious on outright long ISRG until the next print shows procedure growth continuing to exceed placements; the thesis is falsified if procedure growth decelerates into the high-single digits or instrument/service growth meaningfully tracks below utilization.
• Pair trade: long MDT / short ISRG for 1-3 months if you want to express competition risk. The trade works only if MDT’s robotics progress is gaining credibility; cover if ISRG re-accelerates system placements or management guides to sustained double-digit procedure growth.
• Use JNJ as a lower-conviction hedge against an ISRG long: long ISRG / short JNJ only makes sense if you believe the market is underpricing optionality in robotics adoption; otherwise, JNJ’s diversification makes it a poor pure-play short.
• If entering ISRG on weakness, scale in only after confirmation that installed-base utilization remains robust; best risk/reward is after the market stops extrapolating placement volatility into annuity erosion.
• Watch the next quarterly mix: if instrument/accessory revenue continues to outgrow system sales by a wide margin, the selloff is likely overdone and can justify a tactical long despite competition.